Tags

Type your tag names separated by a space and hit enter

Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
Alzheimer Dis Assoc Disord. 2007 Jan-Mar; 21(1):60-4.AD

Abstract

Memantine, an N-methyl-D-aspartate receptor antagonist, is approved in the United States and Europe for the treatment of moderate to severe Alzheimer disease (AD) and has also been investigated in patients with mild to moderate AD. To characterize the specific cognitive benefits of memantine in patients with mild to moderate AD, a post hoc analysis was conducted of a 24-week randomized, double-blind, placebo-controlled, clinical trial comparing memantine (10 mg twice daily) to placebo. Cognition was assessed using the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) total score, individual items, and aggregated subscales, using a mixed model repeated measures analysis. As assessed by the ADAS-cog total score, participants in the placebo group demonstrated significantly more cognitive decline from baseline than participants treated with memantine at all visits beginning at week 8. Subjects treated with placebo also declined significantly more than individuals in the memantine group on 5 of 11 ADAS-cog individual items: orientation, language, comprehension, word finding, and recall of test instructions. Out of 3 ADAS-cog aggregated item subscales (language, memory, and praxis), outcomes in 2 (language and memory) favored memantine. Consistent with findings from trials conducted in moderate to severe AD patients, this post hoc analysis of a randomized clinical trial suggests that memantine benefits core aspects of language and some aspects of memory in patients with mild to moderate AD.

Links

Aggregator Full Text

Authors+Show Affiliations

Pomara N
Nathan S. Kline Institute and New York University School of Medicine, Orangeburg, NY 10962, USA. POMARA@NKI.RFMH.ORG
Ott BR
No affiliation info available
Peskind E
No affiliation info available
Resnick EM
No affiliation info available

MeSH

AgedAged, 80 and overAlzheimer DiseaseCognition DisordersCohort StudiesDouble-Blind MethodExcitatory Amino Acid AntagonistsFemaleHumansMaleMemantineNeuropsychological TestsSeverity of Illness IndexTreatment Outcome

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17334274

Citation

Pomara, Nunzio, et al. "Memantine Treatment of Cognitive Symptoms in Mild to Moderate Alzheimer Disease: Secondary Analyses From a Placebo-controlled Randomized Trial." Alzheimer Disease and Associated Disorders, vol. 21, no. 1, 2007, pp. 60-4.
Pomara N, Ott BR, Peskind E, et al. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial. Alzheimer Dis Assoc Disord. 2007;21(1):60-4.
Pomara, N., Ott, B. R., Peskind, E., & Resnick, E. M. (2007). Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial. Alzheimer Disease and Associated Disorders, 21(1), 60-4.
Pomara N, et al. Memantine Treatment of Cognitive Symptoms in Mild to Moderate Alzheimer Disease: Secondary Analyses From a Placebo-controlled Randomized Trial. Alzheimer Dis Assoc Disord. 2007 Jan-Mar;21(1):60-4. PubMed PMID: 17334274.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial. AU - Pomara,Nunzio, AU - Ott,Brian R, AU - Peskind,Elaine, AU - Resnick,E Malca, PY - 2007/3/6/pubmed PY - 2007/5/16/medline PY - 2007/3/6/entrez SP - 60 EP - 4 JF - Alzheimer disease and associated disorders JO - Alzheimer Dis Assoc Disord VL - 21 IS - 1 N2 - Memantine, an N-methyl-D-aspartate receptor antagonist, is approved in the United States and Europe for the treatment of moderate to severe Alzheimer disease (AD) and has also been investigated in patients with mild to moderate AD. To characterize the specific cognitive benefits of memantine in patients with mild to moderate AD, a post hoc analysis was conducted of a 24-week randomized, double-blind, placebo-controlled, clinical trial comparing memantine (10 mg twice daily) to placebo. Cognition was assessed using the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) total score, individual items, and aggregated subscales, using a mixed model repeated measures analysis. As assessed by the ADAS-cog total score, participants in the placebo group demonstrated significantly more cognitive decline from baseline than participants treated with memantine at all visits beginning at week 8. Subjects treated with placebo also declined significantly more than individuals in the memantine group on 5 of 11 ADAS-cog individual items: orientation, language, comprehension, word finding, and recall of test instructions. Out of 3 ADAS-cog aggregated item subscales (language, memory, and praxis), outcomes in 2 (language and memory) favored memantine. Consistent with findings from trials conducted in moderate to severe AD patients, this post hoc analysis of a randomized clinical trial suggests that memantine benefits core aspects of language and some aspects of memory in patients with mild to moderate AD. SN - 0893-0341 UR - https://www.unboundmedicine.com/medline/citation/17334274/Memantine_treatment_of_cognitive_symptoms_in_mild_to_moderate_Alzheimer_disease:_secondary_analyses_from_a_placebo_controlled_randomized_trial_ L2 - https://doi.org/10.1097/WAD.0b013e318032cf29 DB - PRIME DP - Unbound Medicine ER -